FDA to Re-Evaluate Banned Peptides in 2026-2027

The U.S. Food and Drug Administration (FDA) said on Wednesday it will convene advisory discussions in July 2026 and February 2027 to reconsider limits on 12 peptides that the agency has described as unproven and previously associated with significant safety risks.

The substances were removed in 2023 from the list of ingredients that compounding pharmacies could use. The FDA’s new timetable sets up a formal re-evaluation process through the Pharmacy Compounding Advisory Committee (PCAC) , which is expected to conduct the reviews.

Officials linked the decision to advocacy from Robert F. Kennedy Jr. , who has publicly supported the use of these peptides. The announcement has drawn criticism from some observers who argue that the planned meetings do not appear to be driven by newly presented safety or effectiveness evidence, and who say the process could be shaped by external pressure rather than scientific findings.

The FDA said the PCAC currently has three voting members and one industry representative, while six positions remain unfilled, including the chairperson role. The committee’s composition and vacancies are part of the backdrop as the agency prepares for the two scheduled sessions.

The 12 peptides identified for review are BPC-157 , KPV , TB-500 , MOTs-C , Emideltide , Semax , Epitalon , Cathelicidin , GHK-Cu , Dihexa-acetate , Melanotan II , and Mechano Growth Factor, Pegylated . The substances are often marketed online for a range of health-related claims that have not been proven, even as the FDA has previously cited significant safety risks.

In outlining the context, the FDA pointed to the broader framework for how medicines are typically evaluated in the United States. The standard pathway for new drugs generally involves extensive scientific review of safety and efficacy before products can be marketed for medical use, a process that differs from the way compounded products can be prepared under certain conditions.

The upcoming advisory meetings place renewed attention on how regulators balance patient safety, compounding practices, and public demand for products promoted outside established evidence standards. For stakeholders, the key uncertainty is what information will be presented to the PCAC during the July 2026 and February 2027 sessions, and whether any changes to the current restrictions will be supported by data discussed in those forums.